MATA1 Antibody

What is MATA1 and why are antibodies against it important in research?

MATA1 (Methionine Adenosyltransferase 1A) is a gene encoding the methionine adenosyltransferase I enzyme that catalyzes the formation of S-adenosylmethionine from methionine and ATP. This enzyme plays a crucial role in methionine metabolism and methylation processes throughout the body . Antibodies against MATA1 are valuable research tools for studying methionine metabolism disorders, including methionine adenosyltransferase deficiency, which can be caused by both recessive and dominant mutations . These antibodies enable researchers to detect and quantify MATA1 protein expression in various tissues and cell types, providing insights into metabolic regulations and disease mechanisms.

It's important to note that confusion sometimes arises between MAT1A antibodies and MAT-1 antibody, which is a monoclonal antibody specifically recognizing human tyrosinase used in pigmentation research .

What are the key characteristics of commercially available MATA1 antibodies?

Commercial MATA1 antibodies typically recognize the full-length human MAT1A protein and are available in polyclonal and monoclonal formats. For example, the polyclonal antibody described in the search results was raised against the complete human MAT1A protein and may cross-react with MAT2A, a related protein . Western blot analysis using this antibody typically detects a single band around 44-50kD in liver tissue, which is the primary site of MAT1A expression .

The specificity of antibodies is crucial for accurate research results. When selecting a MATA1 antibody, researchers should consider:

• Immunogen used for antibody generation

• Species reactivity

• Potential cross-reactivity with related proteins (particularly MAT2A)

• Validated applications (Western blot, immunohistochemistry, etc.)

• Clonality (monoclonal vs. polyclonal)

How does MATA1 differ from related proteins like MAT2A?

When using MATA1 antibodies, researchers should be aware that some antibodies might cross-react with MAT2A due to sequence similarities between these related proteins . This cross-reactivity should be carefully evaluated, especially when studying tissues that express both proteins.

What are the validated applications for MATA1 antibodies in research?

MATA1 antibodies have been validated for several experimental applications, each requiring specific optimization:

• Western Blotting: MATA1 antibodies can detect a single band around 44-50kD in liver tissue samples . For optimal results, researchers should use fresh tissue lysates and include appropriate positive controls (liver tissue) and negative controls.

• Immunohistochemistry: Useful for localizing MATA1 protein in tissue sections, particularly liver tissues where MAT1A is predominantly expressed.

• Immunofluorescence: Enables visualization of cellular localization patterns of MATA1 protein.

• Immunoprecipitation: Can be used to isolate MATA1 protein complexes for further analysis of protein-protein interactions.

• ELISA: Quantitative measurement of MATA1 protein levels in clinical samples.

Each application requires specific optimization steps depending on the antibody used and the experimental system.

How should researchers validate MATA1 antibody specificity?

Validating antibody specificity is crucial for reliable research results. For MATA1 antibodies, researchers should:

• Positive Control Testing: Analyze liver tissue samples, which naturally express high levels of MAT1A .

• Negative Control Testing: Examine tissues or cell lines known not to express MAT1A or use MAT1A knockout models.

• Cross-Reactivity Assessment: Test the antibody against purified MAT2A protein to evaluate potential cross-reactivity .

• Peptide Competition Assay: Pre-incubate the antibody with the immunizing peptide to block specific binding sites.

• Alternative Antibody Validation: Compare results with antibodies raised against different epitopes of the same protein.

• Genetic Models: Use siRNA/shRNA knockdown or CRISPR knockout models to confirm specificity.

• Mass Spectrometry Confirmation: Identify immunoprecipitated proteins using mass spectrometry to confirm antibody target.

This comprehensive validation approach ensures that experimental results reflect true MATA1 protein dynamics rather than artifacts.

What are the optimal conditions for Western blot analysis using MATA1 antibodies?

When running Western blots with MATA1 antibodies, researchers should be aware that the antibody may detect a single band around 44-50kD in liver tissue samples . Optimization of antibody concentration is essential for each new lot of antibody.

How can researchers troubleshoot non-specific binding with MATA1 antibodies?

Non-specific binding is a common challenge when working with antibodies. For MATA1 antibodies, consider these troubleshooting approaches:

• Increase Blocking Time/Concentration: Use 5% BSA instead of milk for blocking if background persists.

• Adjust Antibody Concentration: Titrate primary antibody to determine optimal concentration.

• Increase Washing Steps: Add additional washing steps with 0.1% Tween-20 in PBS or TBS.

• Pre-absorb Antibody: Incubate antibody with tissues/cells lacking the target protein before use.

• Address Cross-Reactivity: If cross-reactivity with MAT2A is suspected, use tissues with differential MAT1A/MAT2A expression for validation .

• Optimize Incubation Conditions: Reduce incubation time or temperature for primary antibody.

• Use Alternative Blocking Agents: Try different blocking agents if milk or BSA aren't effective.

• Filter Antibody Solution: Centrifuge diluted antibody briefly to remove potential aggregates.

Proper validation and optimization are key to minimizing non-specific binding and obtaining clean, reliable results.

How do MATA1 antibodies compare with antibodies targeting similar proteins?

Understanding the distinctions between antibodies targeting related proteins is essential for proper experimental design:

It's critical to distinguish between MAT1A antibodies and MAT-1 antibody (against tyrosinase), as these target entirely different proteins despite similar names. The MAT-1 antibody specifically recognizes human tyrosinase and is useful for studying pigmentary disorders and potentially for melanoma diagnosis .

What are the implications of MATA1 mutations for antibody-based detection methods?

Methionine adenosyltransferase deficiency is caused by both recessive and dominant mutations in the MAT1A gene . These mutations can affect antibody-based detection in several ways:

Researchers studying MAT1A mutations should consider using multiple antibodies targeting different epitopes to ensure comprehensive detection. Additionally, genetic analysis alongside protein detection provides complementary information about mutation status.

How can MATA1 antibodies be used in studying liver disease progression?

MATA1 antibodies serve as valuable tools for investigating liver pathologies, offering insights into disease mechanisms:

• Hepatocellular Carcinoma (HCC): MAT1A expression is frequently downregulated in HCC. Antibody-based detection can help track this downregulation during disease progression.

• Cirrhosis: Changes in MAT1A expression patterns can be monitored using immunohistochemistry with MATA1 antibodies.

• Non-alcoholic Fatty Liver Disease (NAFLD): MATA1 antibodies can help assess alterations in methionine metabolism associated with NAFLD development.

• Liver Regeneration: Following partial hepatectomy or liver injury, MATA1 antibodies can be used to monitor changes in MAT1A expression during regenerative processes.

• Drug-Induced Liver Injury: Antibody-based detection of MAT1A can help evaluate metabolic responses to hepatotoxic compounds.

Research protocols typically involve immunohistochemical analysis of liver biopsies or Western blot analysis of liver tissue lysates, with careful attention to standardized sample collection and processing to enable valid comparisons between healthy and diseased states.

What considerations apply when using MATA1 antibodies in immunohistochemistry?

Immunohistochemistry (IHC) with MATA1 antibodies requires careful optimization:

• Fixation Method: Formalin-fixed, paraffin-embedded (FFPE) tissues are commonly used. Fixation time should be standardized (typically 24 hours) to ensure consistent results.

• Antigen Retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is often effective for MATA1 antibodies, but optimization may be required.

• Blocking Protocol: 5-10% normal serum from the same species as the secondary antibody helps reduce background staining.

• Antibody Dilution: Typically 1:100 to 1:500, but this must be optimized for each antibody and application.

• Incubation Conditions: Overnight incubation at 4°C often yields optimal results with minimal background.

• Detection System: HRP-conjugated secondary antibodies with DAB substrate provide good visualization of MATA1 expression.

• Counterstaining: Hematoxylin counterstaining helps visualize tissue architecture alongside MATA1 expression.

• Controls: Include liver tissue as a positive control, as it naturally expresses high levels of MAT1A .

Researchers should be aware that MAT1A expression is primarily cytoplasmic in hepatocytes, and staining patterns should be interpreted accordingly.

How are MATA1 antibodies being used in multi-omics research approaches?

MATA1 antibodies are increasingly integrated into multi-omics research frameworks:

• Proteogenomics: Combining MAT1A genotyping with antibody-based protein detection to correlate genetic variations with protein expression patterns.

• Metabolomics Integration: Using MATA1 antibodies in conjunction with metabolomic profiling to link MAT1A expression levels with S-adenosylmethionine and related metabolite concentrations.

• Phosphoproteomics: Investigating post-translational modifications of MAT1A using specialized antibodies that recognize phosphorylated forms of the protein.

• Single-Cell Analysis: Applying MATA1 antibodies in single-cell protein profiling to understand cell-to-cell variability in expression patterns.

• Spatial Transcriptomics Correlation: Combining antibody-based protein localization with spatial transcriptomics to map expression patterns within tissue architecture.

This integrated approach provides more comprehensive insights into methionine metabolism regulation in health and disease than any single methodology alone.

What is the current state of research on MATA1 antibodies for diagnostic applications?

While primarily research tools, MATA1 antibodies show potential in diagnostic applications:

• Liver Disease Biomarkers: Changes in MAT1A expression may serve as biomarkers for liver pathologies, detectable via antibody-based assays.

• Methionine Adenosyltransferase Deficiency Diagnosis: Antibody-based detection methods could complement genetic testing for this inherited metabolic disorder .

• Hepatocellular Carcinoma Screening: Decreased MAT1A expression is associated with HCC development, potentially detectable in biopsy samples using immunohistochemistry.

• Monitoring Treatment Response: Antibody-based assays may help monitor restoration of normal methionine metabolism during therapeutic interventions.